Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Byetta Prescribers for Diabetes: Endocrinologists (US)(?)

Council Members in this Study Group: 117

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Joseph Bass, MD, PhD
Division Head of Endocrinology and Metabolism
Evanston Northwestern Healthcare

Joseph Bass, MD, PhD, is Assistant Professor of Medicine and Neurobiology at Northwestern University in Illinois and Division Head of Endocrinology and Metabolism at Evanston Northwestern Healthcare. He is also the Director of a federally-funded basic research program on obesity, diabetes, and lipid...

Harold Bays, MD, FACP, President and Medical Director, L-MARC Research CenterHarold Bays, MD, FACP
President and Medical Director
L-MARC Research Center

Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...

Dan Streja, MD
Clinical Professor of Medicine
University of California, Los Angeles

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has...

Michael Dempsey, Medical Director, Johns Hopkins Diabetes Center at Suburban HospitalMichael Dempsey
Medical Director
Johns Hopkins Diabetes Center at Suburban Hospital

Michael Dempsey, MD, is a Private Practitioner in Rockville, Maryland. He is the Medical Director of the Johns Hopkins Diabetes Center at Suburban Hospital, where he is also the Medical Director of Diabetes Education and Endocrine Subsection Chair. He is the Vice-President of the Mid-Atlantic chapter...

George Griffing, MD
Director of General Internal Medicine
Saint Louis University

George Griffing, MD, is Director of General Internal Medicine at St. Louis University. Dr. Griffing’s clinical expertise includes the diagnosis and treatment of diabetes. His research interests include the clinical investigation of inhaled insulin, nasal insulin and pramlintide. Dr. Griffing is a...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Courage trial should redefine care in America | 08-18-2008
Author: GLG Expert Contributor

Most hospitals are financially built on their heart programs. The "agressive" medical arm is conservative by our standards yet as good as stents at far less cost. If this was truly pursued by large companies with TPA insurance plans, their overall cost would drop with large savings in healthcare costs....

Byetta saves lives | 08-18-2008
Author: GLG Expert Contributor

The ACCORD trial results were no suprise to our diabetes practice. We have been heavy users of Byetta since launch in 2005, and have seen the same results in our population of > 2000 diabetics with over 700 on Byetta. Since the Simpson et al study in the Canadian Journal of Medicine (CMAJ 2006;174(2):169-74)...

Byetta Preventing Mortality? Even IF True, Wrong Formulation? | 08-11-2008
Author: GLG Expert Contributor

The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point.  Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...

Cost implications of July 1-2 FDA panel | 07-07-2008
Author: GLG Expert Contributor

Therapeutic effects of drugs are seen essentially in all treated patients.  Adverse outcomes are infrequent.  The July 1-2 FDA diabetes panel recommendation that sturdy systems for determining outcome should be required for all new diabetes treatments may lead to a >100-fold increase in...

Race to Market, with Competition Hot on Heels | 06-19-2008
Author: GLG Expert Contributor

As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Government/Military Hospital or Clinic
  • Private/For-Profit Healthcare Research Entity

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Physician - Division Head
  • President
  • Partner
  • Director
  • Physician - Department Chair

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-08-28T01:45:15.043